Summary
Plasma concentration and urinary excretion of total and 2 active metabolites of metoprolol have been studied in patients with varying degrees of renal impairment and in healthy subjects after intravenous and oral administration of 20 and 50mg of 3H-metoprolol tartrate respectively.
Renal clearance of total metabolites correlated directly with 51Cr-EDTA clearance (r = 0.95, p < 0.001). A reduction of glomerular filtration rate (GFR) by 70 to 80% increased the elimination half-life of total metabolites and of the active metabolite α-hydroxymetoprolol about 3-fold.
Significant accumulation was, however, only observed in the patients with a GFR of about 5ml/min. Even in these patients, the contribution of α-hydroxymetoprolol to the β-adrenoceptor blocking effect of metoprolol will be negligible. The second active metabolite studied is eliminated via biotransformation, and the urinary excretion as well as the plasma concentration of this metabolite were extremely low in comparison with those of the parent drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Åblad, B.; Borg, K.O.; Johansson, G.; Regård, C-G. and Sölvell, L.: Combined pharmacokinetic and pharmacodynamic studies of alprenolol and 4-hydroxy-alprenolol in man. Life Sciences 14: 693–704 (1974).
Arfwidsson, A.; Borg, K.O.; Hoffmann, K-J. and Skånberg, I.: Metabolism of metoprolol in the rat in vitro and in vivo. Xenobiotica 6: 691–711 (1976).
Bennet, W.M.; Singer, I.; Golper, T.; Feig, P. and Coggins, C.J.: Guidelines for drug therapy in renal failure. Annals of Internal Medicine 86: 754–783 (1977).
Borg, K.O.; Carlsson, E.; Hoffmann, K-J.; Jönsson, T-E.; Thorin, H. and Wallin, B.: Metabolism of metoprolol-(3H) in man, the dog and the rat Acta Pharmacologica et Toxicologica 36(Suppl. V): 125–135 (1975).
Dettli, L.; Spring, P. and Habersang, R.: Drug dosage in patients with impaired renal function. Postgraduate Medical Journal 46 (Suppl.): 32–35 (1970).
Drayer, D.E.: Pharmacologically active metabolites: Therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clinical Pharmacokinetics 1: 426–443 (1976).
Duchin, K.L. and Schrier, R.W.: Interrelationship between renal haemodynamics, drug kinetics and drug action. Clinical Pharmacokinetics 3: 58–71 (1978).
Ervik, M.: Quantitative determination of metoprolol in plasma and urine by gaschromatography. Acta Pharmacologica et Toxicologica 36(Suppl. V): 136–144 (1975).
Ervik, M.; Hoffmann, K-J. and Kylberg-Hansen, K.: Multiple ion monitoring of metoprolol and two metabolites in plasma and urine with deuterated internal standards. Biomedical Mass Spectrometry. In press (1980).
Fabre, J. and Balant, L.: Renal failure, drug pharmacokinetics and drug action. Clinical Pharmacokinetics 1: 99–120 (1976).
Gibson, T.P. and Nelson. H.A.: Drug kinetics in artifical kidneys. Clinical Pharmacokinetics 2: 403–426 (1977).
Jordö, L.; Attman, P.O.; Aurell, M.; Johansson, L.; Johnsson, G. and Regårdh, C-G.: Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clinical Pharmacokinetics 5: 169–180 (1980).
Kaye, C.M.; Kumana, C.R.; Leighton, M.; Hamer, J. and Turner, P.: Observations on the pharmacokinetics of acebutolol. Clinical Pharmacology and Therapeutics 19: 416–420 (1976).
Paterson, J.W.; Conolly, N.E.; Dollery, C.T.; Hayes, A. and Cooper, R.G.: The pharmacodynamics and metabolism of propranolol in man. Pharmacologica Clinica (European Journal of Clinical Pharmacology) 2: 127–133 (1970).
Regårdh, C-G., Borg, K.O., Johansson, R.; Johnsson, G. and Palmer, L.: Pharmacokinetic studies on the selective β1-receptor antagonist metoprolol in man. Journal of Pharmacokinetics and Biopharmaceutics 2: 347–364 (1974).
Regårdh, C-G.; Ek, L. and Hoffmann, K-J.: Plasma levels and beta-blocking effect of α-OH-metoprolol — a metabolite of metoprolol — in the dog. Journal of Pharmacokinetics and Biopharmaceutics 7: 471–479 (1979).
Regårdh, C-G.; Johnsson, G.; Jordö, L. and Sölvell, L.: Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacologica et Toxicologica 36(Suppl. V): 45–58 (1975).
Seiler, K-U.; Schuster, K.J.; Meyer, G-J.; Niedermeyer, W. and Wassermann, O.: The pharmacokinetics of metoprolol and its metabolites in dialysis patients. Clinical Pharmacokinetics 5: 192–198 (1980).
Spring, P.: Calculation of drug dosage regimens in patients with renal disease: A new nomographic method. International Journal of Clinical Pharmacology 11: 76–80 (1975).
Thompson, F.D.; Joekes, A.M. and Foulkes, D.M.: Pharmacodynamics of propranolol in renal failure. British Medical Journal 2: 434–436 (1972).
Tjandramaga, T.B.; Verbesselt, R.; Verbeeck, R.; Verberekmoes, R. and De Schepper, P.J.: Disposition of acebutolol and its N-acetyl metabolite in renal insufficiency. Abstract 2300 in VII-th International Conference in Pharmacology. (Paris 1978).
Welling, P.G.; Craig, W.A. and Kunin, C.M.: Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clinical Pharmacology and Therapeutics 18: 45–52 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoffmann, KJ., Regårdh, CG., Aurell, M. et al. The Effect of Impaired Renal Function on the Plasma Concentration and Urinary Excretion of Metoprolol Metabolites. Clin Pharmacokinet 5, 181–191 (1980). https://doi.org/10.2165/00003088-198005020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198005020-00005